eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
eXoZymes (NASDAQ:EXOZ) and its spinout NCTx have achieved a significant biomanufacturing breakthrough, producing 4 grams of N-trans-caffeoyltyramine (NCT) with over 99% purity and 96% yield using their AI-driven exozymes platform.
The project progressed from concept to gram-scale production in just 5 months, significantly faster than traditional synthetic biology approaches. NCT, naturally found in trace amounts in hemp seeds (less than 0.014%), has shown potential benefits for liver fat metabolism, gut barrier function, and mitochondrial activity.
The company plans to scale production 100X over the next six months and is preparing for GMP pilot scale production in 2026. The bioactive ingredients market represents a $216 billion opportunity with 7.6% CAGR globally. eXoZymes is actively seeking early access partners under material transfer agreements.
eXoZymes (NASDAQ:EXOZ) e la sua spin-off NCTx hanno raggiunto un importante traguardo nella bioproduzione, ottenendo 4 grammi di N-trans-caffeoiltramina (NCT) con una purezza superiore al 99% e una resa del 96% grazie alla loro piattaforma AI-driven di exozimi.
Il progetto è passato dal concetto alla produzione su scala grammo in soli 5 mesi, molto più rapidamente rispetto ai metodi tradizionali di biologia sintetica. L'NCT, presente in tracce naturali nei semi di canapa (meno dello 0,014%), ha mostrato potenziali benefici per il metabolismo dei grassi nel fegato, la funzione della barriera intestinale e l'attività mitocondriale.
L'azienda prevede di incrementare la produzione di 100 volte nei prossimi sei mesi e si sta preparando per la produzione pilota GMP nel 2026. Il mercato degli ingredienti bioattivi rappresenta un'opportunità da 216 miliardi di dollari con un CAGR globale del 7,6%. eXoZymes sta attivamente cercando partner per accessi anticipati tramite accordi di trasferimento materiale.
eXoZymes (NASDAQ:EXOZ) y su spinout NCTx han logrado un avance significativo en la bioproducción, fabricando 4 gramos de N-trans-cafeoiltramina (NCT) con más del 99% de pureza y un rendimiento del 96% utilizando su plataforma de exozimas impulsada por IA.
El proyecto pasó de la idea a la producción a escala de gramos en solo 5 meses, mucho más rápido que los enfoques tradicionales de biología sintética. La NCT, que se encuentra de forma natural en trazas en semillas de cáñamo (menos del 0,014%), ha demostrado beneficios potenciales para el metabolismo de grasas hepáticas, la función de la barrera intestinal y la actividad mitocondrial.
La empresa planea incrementar la producción 100 veces en los próximos seis meses y se está preparando para la producción piloto a escala GMP en 2026. El mercado de ingredientes bioactivos representa una oportunidad de 216 mil millones de dólares con un CAGR global del 7,6%. eXoZymes está buscando activamente socios para acceso temprano bajo acuerdos de transferencia de material.
eXoZymes (NASDAQ:EXOZ)와 그 스핀아웃 기업 NCTx는 AI 기반의 exozymes 플랫폼을 이용해 순도 99% 이상, 수율 96%의 N-트랜스-카페오일티라민(NCT) 4그램을 생산하는 중요한 바이오제조 성과를 달성했습니다.
이 프로젝트는 개념에서 그램 단위 생산까지 단 5개월 만에 진행되어 기존 합성생물학 방식보다 훨씬 빠릅니다. NCT는 대마씨앗에 극미량(0.014% 미만) 자연적으로 존재하며, 간 지방 대사, 장 장벽 기능, 미토콘드리아 활성에 잠재적 이점을 보여주고 있습니다.
회사는 향후 6개월 내에 생산량을 100배로 확대할 계획이며 2026년에는 GMP 파일럿 규모 생산 준비 중입니다. 생체활성 성분 시장은 전 세계적으로 연평균 성장률 7.6%로 2160억 달러 규모의 기회를 나타냅니다. eXoZymes는 물질 이전 계약 하에 초기 접근 파트너를 적극적으로 찾고 있습니다.
eXoZymes (NASDAQ:EXOZ) et sa spin-off NCTx ont réalisé une avancée majeure en bioproduction, produisant 4 grammes de N-trans-caféoyltyramine (NCT) avec plus de 99 % de pureté et un rendement de 96 % grâce à leur plateforme d'exozymes pilotée par IA.
Le projet est passé du concept à une production à l'échelle du gramme en seulement 5 mois, bien plus rapidement que les approches traditionnelles de biologie synthétique. La NCT, naturellement présente en traces dans les graines de chanvre (moins de 0,014 %), a montré des bénéfices potentiels pour le métabolisme des graisses du foie, la fonction de la barrière intestinale et l'activité mitochondriale.
L'entreprise prévoit de multiplier la production par 100 au cours des six prochains mois et se prépare à une production pilote conforme aux GMP en 2026. Le marché des ingrédients bioactifs représente une opportunité de 216 milliards de dollars avec un taux de croissance annuel moyen mondial de 7,6 %. eXoZymes recherche activement des partenaires pour un accès anticipé sous accords de transfert de matériel.
eXoZymes (NASDAQ:EXOZ) und dessen Spin-off NCTx haben einen bedeutenden Durchbruch in der Bioproduktion erzielt, indem sie 4 Gramm N-trans-Caffeoyltyramin (NCT) mit über 99% Reinheit und 96% Ausbeute mittels ihrer KI-gesteuerten Exozym-Plattform hergestellt haben.
Das Projekt entwickelte sich in nur 5 Monaten vom Konzept zur Gramm-Maßstab-Produktion, deutlich schneller als herkömmliche Ansätze der synthetischen Biologie. NCT, das natürlich in Spuren in Hanfsamen (weniger als 0,014%) vorkommt, zeigt potenzielle Vorteile für den Fettstoffwechsel der Leber, die Darmbarrierefunktion und die mitochondriale Aktivität.
Das Unternehmen plant, die Produktion innerhalb der nächsten sechs Monate um das 100-fache zu skalieren und bereitet sich auf eine GMP-Pilotproduktion im Jahr 2026 vor. Der Markt für bioaktive Inhaltsstoffe stellt eine 216 Milliarden Dollar große Chance mit einer globalen jährlichen Wachstumsrate (CAGR) von 7,6% dar. eXoZymes sucht aktiv nach Partnern für einen frühen Zugang im Rahmen von Materialtransfervereinbarungen.
- Achieved 99% purity and 96% yield in NCT production, demonstrating platform effectiveness
- Rapid development from concept to production in just 5 months at reduced R&D costs
- Plans for 100X production scale increase in next 6 months
- Product already has GRAS (Generally Recognized as Safe) status for functional foods
- Targeting $216 billion bioactive ingredients market growing at 7.6% CAGR
- Current production limited to lab-scale (4 grams)
- Commercial-scale production not yet achieved, pending GMP pilot scale in 2026
- Requires additional partnerships for market expansion
Insights
eXoZymes' breakthrough enables commercial-scale production of valuable NCT compound, opening new market opportunities with 99% purity achievement.
eXoZymes has achieved a significant biomanufacturing milestone with their AI-driven enzyme platform, successfully producing
The rapid development timeline is particularly impressive - moving from concept to gram-scale production in just 5 months, dramatically faster than typical synthetic biology R&D cycles. This accelerated timeline suggests their AI-driven approach is providing substantial advantages in enzyme engineering efficiency.
What makes this commercially significant is NCT's status as Generally Recognized as Safe (GRAS) for functional foods, eliminating a major regulatory hurdle for market entry. The compound's demonstrated effects on liver fat metabolism, gut barrier function, and mitochondrial activity position it well for applications in the
Their commercialization strategy appears well-structured, with plans to scale production 100X over the next six months, providing samples to early access partners while preparing for GMP pilot scale production. The company is already planning for kilogram-scale demand in 2026 followed by ton-scale production. This signals confidence in both their technical capabilities and market demand.
Beyond NCT itself, this demonstration validates eXoZymes' broader technology platform for efficiently producing natural compounds that are difficult to source. Their exozyme approach potentially solves manufacturing challenges for an entire class of valuable bioactive molecules, representing a scalable competitive advantage across multiple markets.
Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a
96% yield and with a purity higher than99% .NCT project went from concept to gram scale production in 5 months and at a fraction of normal SynBio R&D cost.
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
Early access partners under material transfer agreement can sample the product and eXoZymes and NCTx is actively looking to increase the number of partners.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 29, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - together with its spinout NCTx, announced additional numbers from their biomanufacturing breakthrough - achieving a purity higher than
Co-founder and VP of Research, Dr. Tyler Korman, states, "Producing 4 grams of NCT at a purity higher than
Chief Commercial Officer at eXoZymes, Damien Perriman, adds, "The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. While we're already in talks with early access partners, we recognize the importance of milestones like this to demonstrate our potential and commitment to NCT commercialization. We welcome additional partners who understand the massive potential of our disruptive approach with exozymes - and who bring complementary capabilities to further help accelerate this journey from R&D breakthrough to commercial reality. A journey performed at a speed of development I have not seen before in synthetic biology, resulting in our first mover partners getting considerable advantages in speed to market and brand recognition."
Perriman continues, "We're ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale."
View a video of CCO Damien Perriman's comments, right here.
These now achieved critical technical milestones - gram scale production and high purity - validate the pre-scale biomanufacturing of NCT to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts. Naturally found in quantities less than
Demand for bioactive ingredients in functional food is a
Enhanced fat breakdown and mitochondrial output in liver cells
Modulation of gut-related gene expression linked to intestinal balance for better gut health.
For more information, please go to nctx.one or see video interviews here.
Call for early access partners
By partnering with eXoZymes, early access partners gain access to the world's leading cell-free state-of-the-art biomanufacturing platform, which empowers organizations to innovate faster and more efficiently. Interested parties can explore via this link, including the different partnership models:
https://exozymes.com/partners
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
SOURCE: eXoZymes
View the original press release on ACCESS Newswire
FAQ
What breakthrough did eXoZymes (NASDAQ:EXOZ) announce in July 2025?
What is NCT and why is it significant for eXoZymes?
What are eXoZymes' production scale-up plans for NCT?
What is the market potential for eXoZymes' NCT production?
How can partners access eXoZymes' NCT production technology?
